MedX High-Risk High-Impact grant 2021
We have recieved the early career investigator High-Risk High-Impact 2021 Seed Funding from Duke MedX together with the Tata lab. We will integrate experimental biology and deep active learning for the discovery of novel P2RY14 antagonists as potential treatments against inflammatory diseases such as idiopathic pulmonary fibrosis.
More information about our research and the other recepients can be found at https://medx.duke.edu/news-events/news/medx-announces-high-risk-high-impact-2021-seed-funding-recipients
The program was also highlighted by WRAL https://www.wraltechwire.com/2021/10/25/medx-awards-funding-to-three-emerging-duke-health-innovations/